EPS for HTG Molecular Diagnostics, Inc. (HTGM) Expected At $-0.23

March 13, 2018 - By Marie Mckinney

 EPS for HTG Molecular Diagnostics, Inc. (HTGM) Expected At $ 0.23

Analysts expect HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) to report $-0.23 EPS on March, 22.They anticipate $0.53 EPS change or 69.74 % from last quarter’s $-0.76 EPS. After having $-0.46 EPS previously, HTG Molecular Diagnostics, Inc.’s analysts see -50.00 % EPS growth. The stock increased 1.78% or $0.0901 during the last trading session, reaching $5.1501. About 634,243 shares traded. HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) has risen 34.13% since March 13, 2017 and is uptrending. It has outperformed by 17.43% the S&P500.

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Ratings Coverage

Among 3 analysts covering HTG Molecular Diagnostics (NASDAQ:HTGM), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. HTG Molecular Diagnostics had 14 analyst reports since August 24, 2015 according to SRatingsIntel. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, September 12 report. The rating was maintained by H.C. Wainwright on Wednesday, November 8 with “Buy”. Canaccord Genuity maintained HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) on Monday, January 8 with “Buy” rating. The stock of HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) earned “Buy” rating by H.C. Wainwright on Wednesday, August 9. Rodman & Renshaw initiated HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) rating on Monday, August 22. Rodman & Renshaw has “Buy” rating and $5 target. The stock of HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) earned “Buy” rating by H.C. Wainwright on Wednesday, January 24. The firm has “Buy” rating given on Thursday, February 1 by H.C. Wainwright. The firm has “Buy” rating by Canaccord Genuity given on Friday, January 5. H.C. Wainwright maintained HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) rating on Wednesday, December 27. H.C. Wainwright has “Buy” rating and $6.0 target. The firm earned “Buy” rating on Monday, August 24 by Canaccord Genuity.

HTG Molecular Diagnostics, Inc. develops and markets services and products based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company has market cap of $143.40 million. The company's products, HTG Edge and HTG EdgeSeq platforms include instrumentation , consumables comprising assay kits, and software analytics that automate sample processing and profiles various molecular targets from samples a fraction of the size required by prevailing technologies. It currently has negative earnings. The Company’s platforms generate a molecular profiling library for detection using next-generation sequencing.

More news for HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) were recently published by: Streetinsider.com, which released: “HTG Molecular Diagnostics (HTGM) Announces New Australian Patent” on February 26, 2018. Prnewswire.com‘s article titled: “Pre-Market Technical Scan on Medical Research Equities — HTG Molecular …” and published on March 12, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: